Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCNNASDAQ:NEUPNASDAQ:RNAZOTCMKTS:SRNEQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.45+3.0%$2.70$1.27▼$9.47$9.35M1.961.31 million shs7,789 shsNEUPNeuphoria Therapeutics Inc. - Common Stock$5.07-1.9%$5.17$2.12▼$15.24$9.09M0.25426,892 shs6,816 shsRNAZTransCode Therapeutics$0.41-5.9%$1.00$0.22▼$66.33$10.08M1.512.08 million shs1.69 million shsSRNEQSorrento Therapeutics$0.00$0.00$0.00▼$0.42$496K2.25511,766 shs183,772 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+2.99%+16.95%+38.00%+35.83%+18.56%NEUPNeuphoria Therapeutics Inc. - Common Stock-1.93%-0.78%-11.98%-6.28%+506,999,900.00%RNAZTransCode Therapeutics-5.88%+29.49%-17.86%-94.95%-99.94%SRNEQSorrento Therapeutics0.00%-10.00%+28.57%+80.00%-94.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion Therapeutics1.8398 of 5 stars0.03.00.00.03.83.30.6NEUPNeuphoria Therapeutics Inc. - Common Stock1.9339 of 5 stars3.50.00.00.03.30.00.6RNAZTransCode Therapeutics3.243 of 5 stars3.55.00.00.03.60.01.3SRNEQSorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 0.00N/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common Stock 3.00Buy$21.00314.20% UpsideRNAZTransCode Therapeutics 3.00Buy$10.002,359.42% UpsideSRNEQSorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNEQ, RNAZ, NEUP, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $10.003/13/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.002/6/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.002/4/2025NEUPNeuphoria Therapeutics Inc. - Common StockHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $21.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2M4.67N/AN/A$4.62 per share0.75NEUPNeuphoria Therapeutics Inc. - Common Stock$662.72K13.44N/AN/A$7.82 per share0.65RNAZTransCode TherapeuticsN/AN/AN/AN/A$86.32 per shareN/ASRNEQSorrento Therapeutics$62.84M0.01N/AN/A($0.05) per share-0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$1.22N/A∞N/AN/A-55.32%-48.35%5/6/2025 (Estimated)NEUPNeuphoria Therapeutics Inc. - Common Stock-$15.49MN/A0.00N/AN/AN/AN/AN/AN/ARNAZTransCode Therapeutics-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%5/21/2025 (Estimated)SRNEQSorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SRNEQ, RNAZ, NEUP, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/ARNAZTransCode Therapeutics-$2.00N/AN/AN/A$0.30 millionN/A3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 million2/14/2025Q2 2025NEUPNeuphoria Therapeutics Inc. - Common Stock-$2.01-$1.23+$0.78-$1.23N/A$660.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ANEUPNeuphoria Therapeutics Inc. - Common StockN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ASRNEQSorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A5.075.07NEUPNeuphoria Therapeutics Inc. - Common StockN/A2.063.30RNAZTransCode TherapeuticsN/A1.581.58SRNEQSorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%NEUPNeuphoria Therapeutics Inc. - Common Stock15.90%RNAZTransCode TherapeuticsN/ASRNEQSorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics36.10%NEUPNeuphoria Therapeutics Inc. - Common Stock0.69%RNAZTransCode Therapeutics0.10%SRNEQSorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics302.71 million1.73 millionNo DataNEUPNeuphoria Therapeutics Inc. - Common StockN/A1.76 million1.75 millionN/ARNAZTransCode Therapeutics923.34 million677,000Not OptionableSRNEQSorrento Therapeutics800551.28 million536.95 millionNot OptionableSRNEQ, RNAZ, NEUP, and CYCN HeadlinesRecent News About These CompaniesSorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its LiquidationSeptember 3, 2024 | wsj.comSorrento, Naples, Italy Weather Conditionsstar_ratehomeAugust 29, 2024 | wunderground.comSorrento, British Columbia, Canada 10-Day Weather Forecaststar_ratehomeAugust 26, 2024 | wunderground.comSorrento Announces New Board MemberAugust 22, 2024 | br.advfn.comSorrento wins DoJ’s venue-based challenge to bankruptcy filingMarch 12, 2024 | msn.comSorrento’s Bankruptcy Venue Action Is ‘Unprecedented,’ DOJ SaysMarch 9, 2024 | news.bloomberglaw.comLatham, Jackson Walker avoid sanctions over bankruptcy forum shopping disputeFebruary 29, 2024 | reuters.comVirpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex PharmaceuticalsFebruary 27, 2024 | bizjournals.comSorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comSorrento faked venue in bankruptcy filing, Justice Department saysFebruary 21, 2024 | msn.comSorrento Therapeutics Inc (SRNEQ) Earnings Dates & ReportsNovember 18, 2023 | investing.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate ...October 7, 2023 | bakersfield.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock PriceOctober 7, 2023 | finance.yahoo.comScilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted ...October 4, 2023 | bakersfield.comScilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding CompanyOctober 3, 2023 | finance.yahoo.comScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.September 21, 2023 | finance.yahoo.comScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)September 14, 2023 | finance.yahoo.comScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderSeptember 13, 2023 | finance.yahoo.comSorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19September 12, 2023 | finance.yahoo.comScilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available InformationSeptember 11, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRNEQ, RNAZ, NEUP, and CYCN Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.45 +0.10 (+2.99%) As of 04/30/2025 04:00 PM EasternCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP$5.07 -0.10 (-1.93%) As of 04/30/2025 03:59 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.TransCode Therapeutics NASDAQ:RNAZ$0.41 -0.03 (-5.88%) As of 04/30/2025 04:00 PM EasternTransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Sorrento Therapeutics OTCMKTS:SRNEQ$0.0009 0.00 (0.00%) As of 04/29/2025Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
